Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat ...
“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...
The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...
“Norovirus is a significant public health concern that affects millions of people worldwide each year, leading to severe symptoms and, in some cases, hospitalization,” Moderna CEO Stéphane ...
Moderna is developing an mRNA-based vaccine ... Fever or headaches may also occur. Symptoms usually develop 12 to 48 hours after being exposed, and recovery typically occurs within one to three ...